You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Genzyme: New Framingham plant begins shipping Fabrazyme drug

Genzyme Corp. said today that it has begun shipping doses of its Fabrazyme drug from its new plant in Framingham.

The move follows an announcement in January that federal regulators had given Cambridge-based Genzyme the approval to begin producing Fabrazyme at the company’s new Framingham plant. With the Framingham plan coming on line, patients in the United States are now able to return to full dosing in March following a period in which they had to deal with a shortage.

Continue reading below

Fabrazyme is a treatment for Fabry’s disease, a rare enzyme deficiency that causes waste to accumulate in the body.

Fabrazyme had been produced at Genzyme’s facility at Allston Landing in Boston. But problems at that facility caused a temporarily halt in production and a rationing of Fabrazyme. Those production issues have been addressed, and with the Framingham facility now shipping Fabrazyme, patients living outside the United States should be able to resume full doses later in the year, Genzyme said.

To read today’s press release from Genzyme, please click here.

Genzyme is now a unit of Sanofi SA. Last year, the French drug maker purchased Genzyme for $20.1 billion.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.